Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Is Walgreens Boots (WBA) Likely To Disappoint In Q4 Earnings?

Published 10/20/2019, 10:24 PM
Updated 07/09/2023, 06:31 AM

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is slated to release fourth-quarter fiscal 2019 results on Oct 28, before market opens.

In the last reported quarter, the company witnessed a positive earnings surprise of 3.52%. Its earnings outperformed the Zacks Consensus Estimate in three of the last four quarters, the average positive surprise being 1.22%.

Let’s take a look at how things are shaping up prior to this announcement.

Key Catalysts

Within Retail Pharmacy USA division, Walgreens Boots is benefiting from the transfer of prescriptions from Rite Aid stores. We believe that the favorable trend of prescription volume growth and brand inflation in the United States is likely to reflect on the upcoming quarterly results.

Increase in comparable pharmacy sales and comparable prescriptions is also expected to have driven growth in the segment during the fourth quarter of fiscal 2019.

Several developments, including early benefits from new pharmacy contract wins and volume expansion owing to previously-announced pharmacy partnerships, like that of Express Scripts (NASDAQ:ESRX), have been driving growth in this space of late. This is expected to have contributed to the company’s top line.

On the flip side, Walgreens Boots’ revenue growth within the retail Pharmacy USA division of late is getting hampered due by the company’s store optimization program. Further, persistent de-emphasizing of tobacco is hurting growth, which should again get reflected in the quarterly results.

Overall, the Zacks Consensus Estimate for fourth-quarter Retail Pharmacy USA division revenues is pegged at $26.20 billion, indicating a rise of 17.5% from the year-ago reported figure.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Meanwhile, tough market conditions, particularly in retail, have been inducing sluggishness in the Retail Pharmacy International division.Sales decline in Boots U.K. and the impact of temporary industry-wide NHS underfunding and higher generic pricingon the company’s U.K. pharmacy business are expected to show on fourth-quarter results. Meanwhile, Walgreens Boots is investing in new stores and digital content to progress in the U.K. retail segment.

The Zacks Consensus Estimate of $2.78 billion for revenues from the Retail Pharmacy International division suggests a 5.4% drop from the prior-year reported number.

Strong growth in certain emerging markets is likely to have driven the company’s Pharmaceutical Wholesale division during the fourth quarter.

The Zacks Consensus Estimate for Pharmaceutical Wholesale division revenues of $5.69 billion implies 4.6% growth from the year-earlier reported figure.

Earnings Whispers

Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.

Earnings ESP: Walgreens Boots Alliance has an Earnings ESP of -0.12%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank:Walgreens Boots Alliance carries a Zacks Rank #4 (Sell).

Stocks Worth a Look

Here are a few medical stocks worth considering from the same space with the right mix of elements to surpass expectations this earnings season.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) has an Earnings ESP of +1.22% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Vertex Pharmaceuticals (NASDAQ:VRTX) has an Earnings ESP of +2.24% and a Zacks Rank #1.

DENTSPLY SIRONA (NASDAQ:XRAY) has an Earnings ESP of +5.05% and a Zacks Rank of 3.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.